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GABAB receptors (GABABRs) are considered promising drug targets for the treatment of mental health
disorders. GABABRs are obligate heteromers of principal GABAB1 and GABAB2 subunits. GABABRs can
additionally associate with auxiliary KCTD8, 12, 12b and 16 subunits, which also bind the G-protein and
differentially regulate G-protein signaling. It is unknown whether the KCTDs allosterically inﬂuence
pharmacological properties of GABABRs. Here we show that KCTD8 and KCTD16 slightly but signiﬁcantly
increase GABA afﬁnity at recombinant receptors. However, KCTDs clearly do not account for the 10-fold
higher GABA afﬁnity of native compared to recombinant GABABRs. The positive allosteric modulator
(PAM) GS39783, which binds to GABAB2, increases both potency and efﬁcacy of GABA-mediated G-
protein activation ([35S]GTPgS binding, BRET between G-protein subunits), irrespective of whether
KCTDs are present or not. Of note, the increase in efﬁcacy was signiﬁcantly larger in the presence of
KCTD8, which likely is the consequence of a reduced tonic G-protein activation in the combined presence
of KCTD8 and GABABRs. We recorded Kir3 currents to study the effects of GS39783 on receptor-activated
G-protein bg-signaling. In transfected CHO cells and cultured hippocampal neurons GS39783 increased
Kir3 current amplitudes activated by 1 mM of baclofen in the absence and presence of KCTDs. Our data
show that auxiliary KCTD subunits exert marginal allosteric inﬂuences on principal GABABR subunits.
PAMs at principal subunits will therefore not be selective for receptor subtypes owing to KCTD subunits.
However, PAMs can differentially modulate the responses of receptor subtypes because the KCTDs
differentially regulate G-protein signaling.
This article is part of the Special Issue entitled ‘GABAergic Signaling in Health and Disease’.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).mice; A1, adenosine receptor
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Ltd. This is an open access article u1. Introduction
GABABRs are the G-protein-coupled receptors (GPCRs) for GABA,
the main inhibitory neurotransmitter in the mammalian brain.
They play important roles in regulating neuronal excitability and
have been implicated in a variety of neurological and psychiatric
disorders (Gassmann and Bettler, 2012). GABABRs activate Gai/o-
type G-proteins that inhibit adenylyl cyclase via Gai/o and gate ion
channels via Gbg. It is well established that presynaptic GABABRs
inhibit voltage-gated Ca2þ channels and neurotransmitter release.
Postsynaptic GABABRs activate inwardly rectifying Kþ channels
(Kir3 channels) that generate slow inhibitory postsynaptic poten-
tials and inhibit neuronal excitability by local shunting.
GABABRs are heteromeric complexes of GABAB1 and GABAB2
subunits (Gassmann and Bettler, 2012). Two predominant GABAB1
subunit isoforms exist, GABAB1a and GABAB1b, which constitute
heteromeric GABAB(1a,2) and GABAB(1b,2) receptors with similarnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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(Brauner-Osborne and Krogsgaard-Larsen, 1999; Green et al., 2000;
Kaupmann et al., 1998). GABAB1 subunits contain the GABA
binding-site while the GABAB2 subunit couples to the G-protein.
GABAB2 allosterically induces a 10-fold increase in agonist binding-
afﬁnity at GABAB1. However, for unknown reasons, recombinant
GABABRs still have a 10-fold lower agonist binding-afﬁnity than the
native receptors (Kaupmann et al., 1998). GABAB1a and GABAB1b
target GABABRs to pre- and postsynaptic compartments, respec-
tively (Biermann et al., 2010; Vigot et al., 2006). We recently
showed that GABABRs can constitutively associate with homote-
tramers of Kþ channel tetramerization-domain (KCTD) containing
proteins. GABABRs assembled with KCTD8,12,12b and 16 constitute
molecularly and functionally distinct receptor subtypes (Schwenk
et al., 2010). The KCTDs are cytoplasmic proteins that simulta-
neously bind to GABAB2 and the Gbg subunits of the heterotrimeric
G-protein (Turecek et al., 2014). Dual binding to receptor and G-
protein allows the KCTDs to stabilize the G-protein/receptor inter-
action, which overcomes the slow diffusion-limited association of
the G-proteinwith the receptor and accelerates G-protein signaling
(Turecek et al., 2014). Furthermore, KCTD12 uncouples Gbg from
effector channels to induce a fast (within seconds) and pronounced
current desensitization (Turecek et al., 2014). The prototypical
synthetic GABABR agonist baclofen is 3e7 fold more potent in
activating Kir3 currents in the presence of KCTD proteins (Schwenk
et al., 2010). Whether this increase in agonist potency in the pres-
ence of the KCTDs relates to an increase in agonist afﬁnity at
GABAB1 or to activity-dependent effects at the G-protein, for
example to an acceleration of the G-protein cycle, is unknown.
The ternary GABABR complex assembled from GABAB1, GABAB2,
KCTD and G-protein subunits offers ample opportunities for allo-
steric regulation. For example, it is well established that the
orthosteric agonist binding-site in GABAB1 is allosterically coupled
to the G-protein binding-site in GABAB2 (Hill et al., 1984; Pin et al.,
2004). Likewise, PAMs (GS39783 and CGP7930) that bind to the
GABAB2 transmembrane domains strongly increase agonist
binding-afﬁnity at GABAB1 (Binet et al., 2004; Dupuis et al., 2006;
Mannoury la Cour et al., 2008; Urwyler et al., 2003). Whether as-
sociation of the KCTDs with GABAB2 and the G-protein also allo-
sterically inﬂuences ligand-binding properties of GABABRs is
unknown.
Herewe report that KCTD8 and KCTD16 slightly increase agonist
binding-afﬁnity at the receptor. However, this increase in agonist
binding-afﬁnity is clearly not reaching the still higher afﬁnity of
native GABABRs. Furthermore, GS39783 increases potency and ef-
ﬁcacy of G-protein activation in the presence and absence of the
KCTDs. In summary, our data indicate that the KCTDs exert mar-
ginal allosteric effects on the GABAB1 and GABAB2 protomers and
primarily inﬂuence receptor signaling by acting at the G-protein. A
conclusion from these experiments is that compounds acting at the
GABAB1 and GABAB2 protomers will not allow to clearly distinguish
receptor subtypes based on KCTD subunits. However, our data also
show that by acting at the G-protein the KCTDs can to some extent
differentially affect allosteric modulation of receptor signaling.
2. Materials and methods
2.1. Plasmids, cell culture and transfection procedure
Plasmids encoding Myc-GABAB1b, Myc-GABAB2, Flag-KCTDs, Kir3.1/3.2 con-
catamers, Renilla reniformis luciferase (Rluc)-tagged Gao and Venus-Gg2 were
described previously (Ayoub et al., 2009; Ivankova et al., 2013; Schwenk et al.,
2010). The plasmid expressing Flag-tagged Gb2 was obtained from the Missouri
S&T cDNA Resource Center and pEGFP-N1 from Clontech. The plasmid expressing
Flag-tagged human adenosine receptor 1 (A1) was a gift from Miriam Peeters
(Center for Basic Metabolic Research, Copenhagen University).
Human Embryonic Kidney 293T (HEK293T) and Chinese hamster ovary K1
(CHO) cells were maintained in Dulbecco's modiﬁed Eagle's medium (DMEM,glutamine-free, Invitrogen), supplemented with 10% FCS (Gibco, Life Technolo-
gies) in a humidiﬁed atmosphere of 5% CO2 at 37 C. CHO cells stably expressing
GABAB(1b,2) (CHO-GABAB) were described earlier (Urwyler et al., 2001) and
maintained in DMEM supplemented with 500 mm L-glutamine (Sigma), 40 mg/ml
L-proline (Sigma), 500 mg/ml geneticin (Roche), 250 mg/ml zeocin (Invitrogen) and
10% FCS under identical conditions as HEK293T and CHO cells.
Cultured hippocampal neurons were prepared as described previously (Brewer
et al., 1993). Brieﬂy, embryonic day 16.5 mouse hippocampi were dissected,
digested with 0.25% trypsin (Invitrogen) in 1  PBS solution (Gibco) for 15 min at
37 C, dissociated by trituration, and plated on glass coverslips coated with 1 mg/
ml poly-L-lysine hydrobromide (Sigma) in 0.1 M borate buffer (boric acid/sodium
tetraborate). Neurons were seeded at high density (~550 cells/mm2) and incubated
for 14e21 days in a humidiﬁed atmosphere of 5% CO2 at 37 C. Cultures were grown
in neurobasal medium (Gibco) supplemented with B27 (Invitrogen) and 0.5 mM
L-glutamine.
Lipofectamine 2000 (Invitrogen) was used for all transient transfections of
HEK293T and CHO-GABAB cells. For electrophysiology experiments, CHO-GABAB
cells were splitted at 80e90% conﬂuency 24 h before transfection and plated onto
plastic coverslips (Thermanox, Thermo Fisher Scientiﬁc) at a dilution of 1:5 in
35 mm dishes. CHO-GABAB cells were transfected using 2.5 ml/ml of Lipofect-
amine 2000 as well as 1.75 mg/ml of Kir3.1/3.2 concatamer, 0.625 mg/ml of KCTD
constructs and 0.375 mg/ml of pEGFP-N1 to visualize transfected cells. After 5 h,
the medium was exchanged and the cells were kept in the incubator for addi-
tional 48 h before being used for electrophysiological recordings.
2.2. Viral transduction of CHO cells
For stable expression of Flag-epitope tagged KCTD8 or KCTD12, CHO and
CHO-GABAB cells, were transduced with lentiviral vectors as described earlier
(Lois et al., 2002). Brieﬂy, lentiviruses were produced by cotransfection of
HEK293T cells with the lentiviral target vector FUW (Lois et al., 2002), the HIV-1
packaging vector D8.2 and the VSV-G envelope glycoprotein vector (Oliver
Schlüter, European Neuroscience Institute, G€ottingen). The self-inactivating and
replication-deﬁcient VSV-G pseudotyped viruses were concentrated by ultra-
centrifugation (74,000 g, 90 min, 4 C) of the virus-containing supernatant.
Stable expression of Flag-KCTDs was achieved by transduction of low passage
CHO cells using different concentrations of the virus-containing supernatant to
obtain varying levels of KCTD expression. Pools of CHO cells with equal KCTD-
expression levels were selected by Western blotting of cellular lysates and pro-
teins were detected using an antibody against the Flag-epitope tag (Sigma).
2.3. Radioligand binding assay
Preparation of membranes from HEK293T cells for radioligand binding assays
was performed as described in Galvez et al. (2000). Brieﬂy, culture dishes were
washed twice with ice-cold PBS, 10 mM of HEPES buffer, pH 7.4, was added to the
plates and cells scraped off (BD Flacon). Crude membranes from approximately
ten 15-cm cell culture dishes per point were collected and centrifuged (26,000 g,
20 min). The pellet was re-suspended in 10 ml HEPES buffer, homogenized using
a glass-teﬂon homogenizer (10 strokes) and the suspension centrifuged (38,000 g,
20 min). The pellet was re-suspended in 2 ml of buffer and homogenized (20
strokes). Aliquots were frozen in liquid nitrogen and stored at 80 C for 48 h.
Preparation of membranes from rat cortical neurons as well as mouse brains
for radioligand binding assays was performed as described in Olpe et al. (1990).
Brieﬂy, animals of at least 8 weeks of age were decapitated, the brains removed,
washed in ice-cold PBS and homogenized in 10 volumes of ice-cold 0.32 M su-
crose, containing 4 mM HEPES, 1 m EDTA and 1 mM EGTA, using a glass-teﬂon
homogenizer. Debris was removed at 1000 g (10 min) and membranes centri-
fuged at 26,000 g (15 min). The pellet was osmotically shocked by re-suspension
in a 10-fold volume of ice-cold dH2O and kept on ice for 1 h. The suspension was
centrifuged at 38,000 g (20 min) and re-suspended in a 3-fold volume of dH2O.
Aliquots were frozen in liquid nitrogen and stored at 20 C for 48 h. After
thawing at room temperature, a 7-fold volume of Krebs-Henseleit (KH) buffer (pH
7.4) was added, containing 20 mM Tris-HCl, 118 mM NaCl, 5.6 mM glucose,
4.7 mM KCl, 1.8 mM CaCl2, 1.2 mM KH2PO4 and 1.2 mM MgSO4. Membranes were
washed three times by centrifugation at 26,000 g (15 min), followed by re-
suspension in KH buffer. The ﬁnal pellet was re-suspended in a 5-fold volume
of KH buffer. Aliquots (2 ml) were frozen and stored at 80 C until further use.
On the day of the experiment, the membranes from frozen HEK293T cells or
neurons were thawed, re-suspended in 10 ml of ice-cold dH2O, and centrifuged
at 26,000 g (15 min). The pellet was again re-suspended in 10 ml of ice-cold
dH2O and incubated for 1 h on ice. After one additional round of centrifuga-
tion at 26,000 g (15 min) the ﬁnal pellet was re-suspended in assay buffer
containing 50 mM Tris-HCl buffer (pH 7.7); 10 mM MgCl2, 1.8 mM CaCl2, 100 mM
NaCl, 20 mg of membrane protein, 5 nM of the high-afﬁnity GABABR radioligand
antagonist [3H]CGP54626A (60 Ci/mmol, ANAWA AG, Wangen, Switzerland), in a
ﬁnal volume of 50 ml per point and in the absence and presence of competitor
compound. Protein concentrations for the samples were measured with the
Bradford assay method, using the Bio-Rad protein assay kit and bovine serum
albumin as a standard.
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polypropylene microplates (Greiner Bio-One) with mild shaking. They were
subsequently ﬁltered using 96-well Whatman GF/C glass ﬁber ﬁlters (Perkin
Elmer), pre-soaked in assay buffer, using a Filtermate cell harvester (Perkin
Elmer). After four washes with assay buffer, the Whatman ﬁlter ﬁbers were dried
for 1 h at 50 C. 50 ml of scintillation ﬂuid (Microscint 20, Perkin Elmer) was
added, the plates were shaken for 1 h and thereafter counted using a Packard
TopCount NXT (Perkin Elmer). GraphPad Prism 5.01 software (Graph Pad, San
Diego, CA) was used for data analysis.
2.4. Western Blotting
For Western Blotting, HEK293T cells were harvested, washed in PBS, and
subsequently lysed in a Nonidet P-40 buffer (100 mm NaCl, 1 mm EDTA, 0.5%
Nonidet P-40, 20 mm Tris/HCl, pH 7.4) supplemented with complete EDTA-free
protease inhibitor mixture (Roche). After rotation for 10 min at 4 C, the ly-
sates were cleared by centrifugation at 16,000  g for 10 min at 4 C. Lysates
were thereafter resolved using standard SDS-PAGE and probed with the primary
antibodies rabbit anti-Myc (Sigma), rabbit anti-GABAB1 (Novartis) and guinea pig
anti-GABAB2 (Millipore). The antibody incubation was in 5% nonfat dry milk in
PBS containing 0.1% Tween-20. The chemiluminescence detection kit (Pierce)
was used for visualization.
2.5. [35S]GTPgS binding assay
[35S]GTPgS binding assays with CHO cell membranes were performed as
described (Urwyler et al., 2001). Brieﬂy, CHO cells were grown to 80e90% con-
ﬂuency in 15-cm culture dishes. Culture dishes were washed twice with ice-cold
PBS and subsequently treated as described for the radioligand binding assay with
membranes of HEK293T cells with the following differences. The ﬁnal pellet was
re-suspended in assay buffer containing 50 mM Tris-HCl buffer (pH 7.7); 10 mM
MgCl2, 1.8 mM CaCl2, 100 mM NaCl, 30 mM guanosine 5‘-diphosphate (GDP,
Sigma), 10 mg of membrane protein, 0.2 nM [35S]GTPgS (Perkin Elmer), in the
absence or presence of GS39783 (10 mM, dissolved in DMSO, a kind gift from K.
Kaupmann, Novartis), in a ﬁnal volume of 200 ml per point. Non-speciﬁc binding
was measured in the presence of unlabeled GTPgS (10 mM, Sigma). To determine
basal [35S]GTPgS binding we used 1 mM of GDP in the assay buffer. Because
maximal binding with GABA alone differed between experiments, the data were
normalized to the maximal effect (Emax) of saturating concentrations of GABA in
the absence of GS39783 (100%) and basal activity without GABA (0%).
For [35S]GTPgS binding assays with mouse brain membranes, mice of at least
8 weeks of age were decapitated, the brains removed and subsequently pro-
cessed as described for the radioligand binding assay with brain membranes. On
the day of the experiment, the frozen membranes were thawed, homogenized in
10 ml ice-cold assay buffer and centrifuged at 20,000 g (15 min). The pellet was
re-suspended in the same volume of cold buffer (50 mM Tris-HCl, pH 7.7, 100 mM
NaCl, 10 mM MgCl2, 1.8 mM CaCl2) and centrifuged twice as above with 30 min of
incubation on ice in between the centrifugation steps. The resulting pellet was
re-suspended, homogenized in assay buffer by using a glass/teﬂon homogenizer
and assayed as described above for CHO cell membranes.
2.6. Bioluminescence resonance energy transfer (BRET) measurements
CHO and CHO-GABAB cells were transiently transfected with plasmids
encoding Gao-Rluc, Venus-Gg2, Flag-Gb2 and Myc-KCTD8, Myc-KCTD12 or
Myc-KCTD16 and seeded into 96-well microplates (Greiner Bio-One). Cells were
washed with PBS 24 h after transfection. BRET was measured in an Inﬁnite® F500
microplate reader (Tecan) after injection of 5 mM Coelenterazine h (NanoLight
Technologies). Baclofen was added at a ﬁnal concentration of 10 mM or 100 mM.
GS39783 was added at the ﬁnal concentration of 10 mM, 5 min prior to mea-
surement. Luminescence and ﬂuorescence signals were detected sequentially
with an integration time of 200 ms. The BRET ratio was calculated as the ratio of
light emitted by Venus-Gg2 (530e570 nm) over light emitted by Gao-Rluc
(370e470 nm) and corrected by subtracting ratios obtained with the Rluc fusion
protein alone. The results were expressed in mBRET units determined as net
BRET  1000. Each data point was obtained using duplicate wells. The curves
were ﬁtted using GraphPad Prism 5.01 software (“Plateau followed by one-phase
decay”).
2.7. Electrophysiology
Kir3 currents were recorded at 30e32 C in artiﬁcial cerebrospinal ﬂuid
containing 145 mM NaCl, 2.5 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 25 mM glucose,
10 mM HEPES, pH 7.3. Patch pipettes were pulled from borosilicate glass capil-
laries (resistance of 3e5 MU) and ﬁlled with a solution containing 140 mM K-
gluconate, 4 mM NaCl, 5 mM HEPES, 2 mM MgCl2, 1.1 mM EGTA, 2 mM Na2-ATP,
5 mM phosphocreatine, 0.6 mM Na3-GTP, at pH 7.25 (adjusted with KOH).
GABABR responses were evoked at 50 mV by fast application of 1e100 mM
baclofen (Ascent Scientiﬁc) with a multiple channel perfusion valve control
system (VC-8, 3 barrels, Warner Instruments). Data were acquired with aMultiClamp 700B (Molecular Devices), low-pass ﬁltered at 2 kHz and digitized at
10 kHz using a Digidata 1440A interface (Molecular Devices) driven by pClamp
10.3 software. Whole-cell currents were analyzed using Clampﬁt 10.3 software
(Molecular Devices). Data are expressed as mean ± S.E.M. and were analyzed
with GraphPad Prism 5.01 software. EGFP-expressing CHO cells were identiﬁed
via epiﬂuorescence using an FITC ﬁlter set and patched under oblique illumi-
nation optics (BX51WI; Olympus).
2.8. Statistics
Curves for radioligand displacement and [35S]GTPgS binding at different
GABA concentrations were estimated by nonlinear regression. pKI, pEC50
(log10EC50) and Emax values represent the mean ± S.E.M of at least three inde-
pendent experiments. Levels of statistical signiﬁcance were set at *, p < 0.05; **,
p < 0.01 and ***, p < 0.001. Extra sums-of-squares F-tests were used for pKI and
pEC50, using the GraphPad Prism 5.01 software. Two-way ANOVA, followed by a
post hoc Sidak's multiple comparison test was used for Emax. KruskaleWallis test
followed by Dunn's multiple comparison test was used to determine basal [35S]
GTPgS binding and baseline BRET in the absence of agonist.3. Results
3.1. Effects of the KCTDs on GABA binding-afﬁnity at recombinant
and native GABABRs
In order to determine if the KCTDs allosterically inﬂuence
agonist binding-afﬁnity at GABAB1, we transiently expressed
GABAB1b or GABAB(1b,2) in the absence and presence of KCTD8,
KCTD12 or KCTD16 in HEK293T cells. Approximately equal
expression of ectopic GABAB1b and GABAB2 in cells was veriﬁed
using protein extracts from transiently transfected HEK293T cell
membrane fractions (Suppl. Fig. 1). We used [3H]CGP54626A, a
competitive GABABR antagonist (Kaupmann et al., 1997), for radi-
oligand displacement experiments with membranes of transfected
cells. In agreement with earlier studies (Kaupmann et al., 1997,
1998), the afﬁnity of GABA at GABAB1b was ~10-fold lower than at
the GABAB(1b,2) heteromer and ~100-fold lower than at rat cortical
membranes (Fig. 1A). Co-expression of the KCTDs slightly increased
GABA afﬁnity at GABAB(1b,2) (Fig. 1A and Table 1). This increase in
afﬁnity reached signiﬁcance for KCTD8 and KCTD16 but not for
KCTD12 (F-test). These experiments show that binding of KCTD8 or
KCTD16 to GABAB2 exerts a small positive allosteric effect on the
GABA binding-site of GABAB1. The GABA binding-afﬁnity at all re-
combinant GABABR subtypes analyzed here was still signiﬁcantly
lower than the afﬁnity at native receptors (p < 0.001 for rat cortical
membranes vs. KCTD8, KCTD12 and KCTD16; F-test). It is conceiv-
able that in transfected HEK293T cells distinct receptor populations
contribute to the measured GABA binding-afﬁnity. In line with this
HEK293Tcells transiently transfectedwith GABAB1b in combination
with GABAB2 alone or together with KCTD8, KCTD12, or KCTD16
show Hill coefﬁcients of 0.68, 0.77, 0.66 and 0.72, respectively. In
contrast HEK293T cells transiently transfected with GABAB1b alone
or rat cortical membranes exhibit a Hill coefﬁcient close to 1.0
indicative of a single binding site (Table 1). While it cannot be ruled
out that the deviation of the Hill coefﬁcients from 1 and the lower
overall afﬁnity of recombinant receptors compared to native re-
ceptors are caused by overexpression in HEK293T cells it is also
possible that still unknown factors are responsible for the higher
afﬁnity of native receptors. The GABA binding-afﬁnity of full brain
membranes of wild-type (WT) and Kctd8/12/16/ knock-out (3KO)
mice (Turecek et al., 2014) are similar (p ¼ 0.503; Fig. 1B and
Table 2) and rule out a pronounced effect of the KCTDs on the
overall binding afﬁnity in the mouse brain. In summary, the data
show that KCTD8 and KCTD16 exert a small allosteric effect on the
orthosteric agonist binding-site in a recombinant expression sys-
tem but do not signiﬁcantly inﬂuence the overall agonist binding
afﬁnity in native membranes.
Table 2
Effect of the KCTDs on [3H]CGP54626A displacement from native GABABRs by GABA.
The binding of the orthosteric ligand [3H]CGP54626A to native GABABRs on brain
membranes of wild-type (WT) or Kctd8/12/16/ knockout (3KO) mice was
measured as described in the Materials and Methods section. Displacement curves
were constructed as illustrated in Fig. 1B. The results shown are means ± S.E.M. from
(N) individual experiments. Results are compared to native GABABRs of wild-type
mice using an Extra sums-of-squares F-test.
GABABR pKi GABA (log M) Hill coefﬁcient N
WT 5.58 (±0.10) 0.80 3
3KO 5.50 (±0.06) 0.86 3
Fig. 1. Effects of the KCTDs on [3H]CGP54626A displacement by GABA. (A) [3H]
CGP54626A displacement curves with membranes of HEK293T cells transiently
transfected with either GABAB(1b,2) alone (black triangles, point up) or GABAB(1b,2) in
combination with KCTD8 (blue triangles, point down), KCTD12 (red diamonds) or
KCTD16 (open green circles). [3H]CGP54626A displacement curves with membranes of
HEK293T cells transfected with GABAB1b alone (gray squares) and with GABABRs in rat
cortical membranes (brown circles) are shown as controls. Displacement of [3H]
CGP54626A (5 nM) was performed with increasing concentrations of GABA. Data
points represent means ± S.E.M. of 3e6 independent experiments, each performed in
quadruplicates. A summary of relevant parameters is given in Table 1. (B) [3H]
CGP54626A displacement curves with brain membranes of wild-type (WT, red circles)
or Kctd8/12/16/ triple KO mice (3KO, blue diamonds). Displacement of [3H]
CGP54626A (5 nM) was performed with increasing concentrations of GABA. Data
points represent means ± S.E.M. of 3 independent experiments, each performed in
quadruplicates. A summary of relevant parameters is given in Table 2.
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GABABRs in [
35S]GTPgS binding experiments
To determine whether the KCTDs inﬂuence allosteric modula-
tion of GABABRs by a PAM we used GS39783 in combination with
the [35S]guanosine 50-O-(3-thio)triphosphate ([35S]GTPgS) binding
assay, a well-established functional assay for GABABRs (UrwylerTable 1
Effect of the KCTDs on [3H]CGP54626A displacement by GABA. The binding of the
orthosteric ligand [3H]CGP54626A to recombinant GABABRs on membranes of
HEK293T cells and native GABABRs on rat cortical membranes was measured as
described in the Materials and Methods section. Displacement curves were con-
structed as illustrated in Fig. 1A. The results shown are means ± S.E.M. from (N)
individual experiments.*, p < 0.05,**, p < 0.01,***, p < 0.001 compared to control
GABAB(1b,2) receptors using an Extra sums-of-squares F-test.
GABABR pKi GABA (log M) Hill coefﬁcient N
GABAB(1b,2) 4.16 (±0.04) 0.68 6
GABAB(1b,2) þ KCTD8 4.43 (±0.07)** 0.77 6
GABAB(1b,2) þ KCTD12 4.27 (±0.04) 0.66 6
GABAB(1b,2) þ KCTD16 4.31 (±0.06)* 0.72 6
GABAB1b homomer 3.07 (±0.03)*** 1.11 3
Rat cortical membranes 5.23 (±0.09)*** 0.91 4et al., 2005, 2003). First, we analyzed G-protein activation in
membranes of CHO-GABAB cells stably expressing GABAB(1b,2) in
the absence or presence of KCTDs. For these experiments, we len-
tivirally transduced CHO-GABAB cells (Urwyler et al., 2001) to
generate two additional cell lines stably expressing GABAB(1b,2)
together with KCTD8 or KCTD12. KCTD12 represents KCTD12 and
KCTD12b that both produce desensitizing Kir3 currents upon re-
ceptor activation. In contrast, KCTD8 represents KCTD8 and KCTD16
that produce largely non-desensitizing currents (Schwenk et al.,
2010). [35S]GTPgS binding assays were performed with mem-
branes of all three cell lines, either in the absence or presence of
10 mM of GS39783 (Fig. 2A). Conﬁrming earlier studies (Urwyler
et al., 2005, 2003), we found that GS39783 signiﬁcantly increased
both potency and efﬁcacy of GABA to stimulate [35S]GTPgS binding
in CHO-GABAB control cells (ø KCTD, Table 3). Similarly, GS39783
signiﬁcantly increased both potency and efﬁcacy of GABA at
membranes of CHO-GABAB cells expressing KCTD8 or KCTD12
(Table 3, F-test for potency, two-way analysis of variance (ANOVA)
with subsequent post-hoc Sidak's multiple comparison test for ef-
ﬁcacy). Of note, the KCTDs did not signiﬁcantly alter the potency of
GABA at GABABRs in the absence of GS39783 when compared to
control CHO-GABAB cells (KCTD8: p ¼ 0.677; KCTD12: p ¼ 0.114).
With GS39783-treated membranes the potency in the presence of
KCTD8 but not KCTD12 was signiﬁcantly but slightly decreased
compared to control cells (KCTD8: p ¼ 0.003; KCTD12: p ¼ 0.876).
This supports that KCTD8 exerts a weak allosteric inﬂuence on the
PAM binding-site or the G-protein binding-site in the presence of
the PAM. Furthermore, the GS39783-induced increase in the efﬁ-
cacy was signiﬁcantly higher in the presence of KCTD8 than in
control or KCTD12-expressing CHO-GABAB cells (Fig. 2A, p < 0.001
for KCTD8 vs. ø KCTD and KCTD8 vs. KCTD12), while there was no
signiﬁcant difference in the increase in efﬁcacy between control
and KCTD12-expressing cells (p ¼ 0.0608 for ø KCTD vs. KCTD12).
The above data indicate that GS39783-modulation of the efﬁ-
cacy of GABABR responses is remarkably large with KCTD8. One
possible explanation for the larger increase in efﬁcacy with KCTD8
is that KCTD8 reduces the efﬁcacy in the absence of GS39783. A
similar phenomenon was reported earlier for partial agonists that
are more amenable to allosteric modulation of GABABRs by PAMs
than full agonists (Mannoury la Cour et al., 2008; Urwyler et al.,
2005). In order to determine if KCTD8 reduces basal G-protein
activation of GABABRs, we performed [35S]GTPgS binding assays in
the absence of agonist, but in the presence of a low GDP concen-
tration (1 mM) (Roberts and Strange, 2005) to facilitate detection of
agonist-independent receptor activity (Strange, 2010). Indeed,
KCTD8 (Fig. 2B) led to a small but signiﬁcant decrease in basal G-
protein activation in the unstimulated state (86% of control CHO-
GABAB cells, p ¼ 0.009), while KCTD12 has no such effect (97% of
control, p ¼ 0.654). This indicates that KCTD8 decreases basal G-
protein activation in the absence of agonist.
In summary, these experiments show that GS39783 increases
agonist potency and efﬁcacy both in the absence and presence of
KCTDs in [35S]GTPgS binding experiments. Together with the
Fig. 2. Effects of the KCTDs on allosteric modulation of recombinant GABABRs in [35S]GTPgS binding experiments. (A) GABA-induced [35S]GTPgS binding to membranes of CHO-
GABAB cells stably expressing either GABAB(1b,2) alone (ø KCTD, black triangles, point up) or GABAB(1b,2) in combination with KCTD8 (blue triangles, point down) or KCTD12 (red
diamonds). Filled symbols indicate the absence, empty symbols the presence of GS39783 (10 mM, þGS). Data points represent the stimulation of [35S]GTPgS binding by the indicated
concentrations of GABA above basal binding (0%) normalized to the maximal GABA response in the absence of GS39783 (100%). Data points are means ± S.E.M. of three independent
experiments, each performed in quadruplicates. A summary of relevant parameters is given in Table 3. (B) Summary bar graph of basal [35S]GTPgS binding, performed in the
presence of 1 mM of GDP, in CHO-GABAB cells expressing GABAB(1b,2) without (ø KCTD, black) or with KCTD8 (blue) or KCTD12 (red). One representative experiment out of three is
shown. Results are means ± S.E.M. of quadruplicates. *, p < 0.05 of KruskaleWallis test followed by Dunn's multiple comparison test.
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the KCTDs exert no or little allosteric inﬂuence on allosteric and
orthosteric binding sites in principal receptor subunits. Of note,
KCTD8 reduces the basal level of receptor activity. GS39783 can
overcome reduced G-protein coupling in the presence of KCTD8
and therefore induces a signiﬁcantly larger increase in the maximal
receptor response.3.3. Effects of the KCTDs on allosteric modulation of recombinant
GABABRs in BRET G-protein activation experiments
The [35S]GTPgS binding experiments showed that GS39783 acts
as a PAM in a functional assay in the absence and presence of the
KCTDs. The [35S]GTPgS binding experiments additionally indicated
that KCTD8 reduces basal G-protein activation by the receptor, but
that increased activation can still be obtained in the presence of
GS39783. To corroborate these ﬁndings, we monitored GABABR-
induced G-protein activation in BRET experiments (Digby et al.,
2006; Frank et al., 2005; Turecek et al., 2014). We transiently
transfected CHO-GABAB cells with the donor fusion protein Gao-
Rluc, the acceptor fusion protein Venus-Gg2, Gb2 and each of the
KCTDs. We then determined the magnitude of the BRET changeTable 3
Effects of the KCTDs on allosteric modulation of recombinant GABABRs in [35S]GTPgS
binding experiments. Concentration response curves were measured (Fig. 2) from
membranes of CHO-GABAB cells, stably expressing GABABRs without or with KCTDs,
both in the absence and presence of the positive allosteric modulator GS39783 (GS).
Because the maximal effect of GABA alone differed between experiments, the data
were normalized to the maximal effect (Emax) obtained with saturating concentra-
tions of GABA alone in the absence of GS (100%) and basal activity without GABA
(0%). The results shown are means ± S.E.M from (N) individual experiments.**,
p < 0.01,***, p < 0.001 compared to non- GS-treated control values (Extra sums-of-
squares F-test for pEC50 and two-way ANOVA followed by a post-hoc Sidak's mul-
tiple comparison test for Emax).
pEC50 GABA (- log M) Emax N
ø KCTD 5.3 (±0.1) 97.5 (±7.0) 3
ø KCTD, þGS 6.2 (±0.0)*** 378.4 (±7.3)***
KCTD8 5.2 (±0.2) 100.5 (±15.8) 3
KCTD8, þGS 5.9 (±0.0)** 586.0 (±20.7)***
KCTD12 5.1 (±0.1) 100.0 (±5.9) 3
KCTD12, þGS 6.2 (±0.0)*** 322.8 (±7.0)***between Gao-Rluc and Venus-Gg2 during G-protein activation
induced by baclofen (10 mM and 100 mM) in the absence and
presence of GS39783. Of note, baclofen concentrations lower than
10 mM did not lead to measurable changes in BRET.
GS39783 (10 mM) signiﬁcantly increased the magnitude of the
BRET change induced by baclofen in the absence and presence of
KCTDs (Fig. 3AeC). Of note, we recently reported a signiﬁcantly
larger magnitude of the BRET change with KCTD12, which reﬂects
binding of KCTD12 to an activity-dependent binding-site on the bg
subunits of the G-protein (Turecek et al., 2014). This KCTD12-
speciﬁc conformational rearrangement of the G-protein is only
seen with the high concentration of baclofen. Activity-dependent
binding of KCTD12 to bg requires unbinding of Ga from Gbg
(Turecek et al., 2014) and may therefore depend on substantial G-
protein dissociation, offering a possible explanation for the
requirement of a high baclofen concentration. The KCTD12-speciﬁc
increase in the change of BRET is further increased by GS39783.
This indicates that PAMs and KCTD12 affect the G-protein rear-
rangement independent of each other, with KCTD12 primarily
acting at the G-protein (Turecek et al., 2014).
Interestingly, KCTD8, but not KCTD12 or KCTD16, showed a
signiﬁcantly decreased baseline BRET in the absence of baclofen,
which reﬂects the basal G-protein conformation (Fig. 3B and C,
right, also compare traces of KCTD8 with other traces in Fig. 3A). To
determine if the decreased baseline BRET requires binding of
KCTD8 to GABABR, BRET studies were performed with CHO cells
that lacked GABABRs or expressed adenosine receptor 1 (A1). In
these cells KCTD8 did not signiﬁcantly decrease the baseline BRET
levels when compared to controls (p ¼ 0.793 for CHO cells without
GABABR (n¼ 24); p¼ 0.252 for CHO cells expressing A1 (n¼ 27)). In
summary, the BRET measurements support that GS39783 increases
agonist-induced G-protein activation irrespective of the KCTDs.
Moreover, KCTD8 reduces basal G-protein activation when associ-
ated with GABABRs.3.4. Effects of the KCTDs on allosteric modulation of native GABABRs
in [35S]GTPgS binding experiments
[35S]GTPgS binding and BRET studies show that GS39783 acts as
a PAM at recombinant GABABRs assembled with KCTDs. We further
investigated whether GS39783 exerts PAM activity at native
Fig. 3. Effects of the KCTDs on allosteric modulation of recombinant GABABRs in BRET G-protein activation assays. (A) Representative baclofen-induced changes in the BRET signal
(milli BRET units, mBU) with CHO-GABAB cells co-expressing Gao-Rluc, Venus-Gg2 and Gb2 with or without KCTD8, KCTD12 or KCTD16 in the absence (black) or presence (gray) of
GS39783 (GS, 10 mM, 5 min pre-incubation). (B) Summary bar graph of BRET changes upon 10 mM baclofen application (changes in BRET (DBRET) in % of basal BRET, left) and baseline
BRET (in mBU, right). Data are means ± S.E.M. of eight individual experiments. *, p < 0.05; **, p < 0.01; ***, p < 0.001; compared to the respective DMSO treatment. #, p < 0.001;
compared to all DMSO treatments. $, p < 0.001; compared to all GS treatments. (C) Summary bar graph of BRET changes upon 100 mM baclofen application (left) and baseline BRET
(right). Data are means ± S.E.M. of 4e7 individual experiments. *, p < 0.05; **, p < 0.01; ***, p < 0.001; compared to the respective DMSO treatment. #, p < 0.05; compared to all
DMSO treatments. $, p < 0.01; compared to all GS treatments.
M. Rajalu et al. / Neuropharmacology 88 (2015) 145e154150
Table 4
Effects of the KCTDs on allosteric modulation of native GABABRs in [35S]GTPgS
binding experiments. Concentration response curves were measured (Fig. 4) from
brain membranes of wild-type (WT) or Kctd8/12/16/ knockout (3KO) mice, both in
the absence and presence of the positive allostericmodulator GS39783 (GS). Because
the maximal effect of GABA alone differed between experiments, the data were
normalized to the maximal effect (Emax) obtained with saturating concentrations of
GABA alone in the absence of GS (100%) and basal activity without GABA (0%). The
results shown are means ± S.E.M from (N) individual experiments.*, p < 0.05,***,
p < 0.001 compared to non-GS-treated control values (Extra sums-of-squares F-test
for pEC50 and two-way ANOVA followed by a post-hoc Sidak's multiple comparison
test for Emax).
pEC50 GABA (log M) Emax N
WT 5.4 (±0.1) 100.0 (±0.6) 4
WT, þGS 6.3 (±0.1)*** 196.3 (±27.8)*
3KO 5.3 (±0.1) 100.0 (±0.1) 4
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assay andwhole brainmembranes of 3KOmice. Of note, KCTD12b is
only expressed in the medial habenula and does not substantially
inﬂuence biochemical assays in whole brain membranes (Metz
et al., 2011; Schwenk et al., 2010). As expected, GS39783
increased both potency and efﬁcacy of GABA at GABABRs of wild-
type (WT) mice (Perdona et al., 2011; Urwyler et al., 2003)
(Fig. 4). The lack of KCTDs in 3KOmice did not inﬂuence the potency
of GABA in the absence (p ¼ 0.822) or presence of GS39783
(p ¼ 0.464). Furthermore, the lack of KCTDs did not inﬂuence the
ability of GS39783 to increase the efﬁcacy of GABA in 3KO
membranes (p > 0.999) (Table 4). In summary, GS39783 had similar
PAM activity at native GABABRs irrespective of whether KCTDswere
present or not.3KO, þGS 6.4 (±0.1)*** 193.5 (±28.8)*3.5. Effects of the KCTDs on allosteric modulation of GABABR-
activated Kir3 currents in CHO cells
We next analyzed whether GS39783 allosterically modulates
GABABR-activated Gbg signaling in the presence or absence of
KCTDs. Kir3 currents were evoked every 5 min by a 40 s applica-
tion of baclofen (1 mM, ~EC20, Fig. 5A). This was ﬁrst done in the
absence (GS) and then in the presence of GS39783 (þGS, 10 mM,
bath application for 10 min). GS39783 had no effect on holding
currents (Suppl. Fig. 2A) but led to an approximately two-fold
increase of the Kir3 current peak amplitude both in the absence
and presence of KCTDs (Fig. 5A and B). GS39783 accentuated ki-
netic effects of KCTD12 on GABABR signaling described earlier
(Schwenk et al., 2010; Turecek et al., 2014). Speciﬁcally, GS38793
shortened the rise-time and increased the relative desensitization
of evoked Kir3 currents (Fig 5B). The effects of KCTD12 on rise-
time and desensitization are dependent on the baclofen concen-
tration (Suppl. Fig. 2B and C). It is therefore likely that GS39783
shortens the rise-time and increases desensitization in the pres-
ence of KCTD12 by increasing agonist binding-afﬁnity at the re-
ceptor. Interestingly, GS39783 did not signiﬁcantly increase the
plateau current during prolonged KCTD12-induced desensitization
(þGS39783: 19.7 ± 6.2 pA,GS39783: 13.1 ± 6.0 pA, p ¼ 0.055,
Fig. 5A). Since KCTD12 induces desensitization by interfering withFig. 4. Effects of the KCTDs on allosteric modulation of native GABABRs in [35S]GTPgS
binding experiments. Effect of GS39783 on GABA-induced [35S]GTPgS binding to brain
membranes of wild-type (WT, red circles) or Kctd8/12/16/ triple knockout mice (3KO,
blue diamonds). Filled symbols indicate the absence, empty symbols the presence of
GS39783 (10 mM, þGS). Data points represent the stimulation at different GABA con-
centrations above basal binding (0%) normalized to the maximal GABA response in the
absence of GS39783 (100%). Data points are means ± S.E.M. of four independent ex-
periments, each performed in quadruplicates. A summary of relevant parameters is
given in Table 4.Gbg activation of the Kir3 channel (Turecek et al., 2014) the PAM
activity at the receptor may no longer be very effective during
maximal KCTD12-mediated inhibition of Gbg signaling. Altogether
the data are consistent with the PAM potentiating KCTD12-
mediated effects at the G-protein by increasing agonist afﬁnity at
the receptor and hence receptor activation at a given concentra-
tion of agonist.3.6. Effects of KCTDs on allosteric modulation of GABABR-activated
Kþ currents in hippocampal neurons
KCTD8, 12, 12b and 16 are differentially expressed in the brain
(Metz et al., 2011; Schwenk et al., 2010). KCTD12 and 16 expression
is high in the hippocampus while KCTD8 expression is low in this
area. KCTD12b is exclusively expressed in the medial habenula.
Using cultured hippocampal neurons from 3KO mice and control
WTmicewe analyzedwhether GS39783 has similar PAM activity in
the absence and presence of KCTD proteins.
Native Kþ currents exhibit strong run-down after repeated
baclofen application. We therefore studied the modulatory effect of
GS39783 during steady-state application of baclofen. We applied a
low concentration of baclofen (1 mM) for 1 min and then co-applied
GS39783 (10 mM) for an additional minute (Fig 6). Baclofen evoked
Kþ currents exhibited little desensitization. GS39783 increased the
Kþ-current amplitude both inWTand 3KO neurons. This increase in
amplitude was not signiﬁcantly different between 3KO (27 ± 5%)
and WT (40 ± 9%) neurons (p ¼ 0.40). This result conﬁrms that
GS39783 is equally effective as a PAM at native GABABRs with or
without KCTDs.4. Discussion
It is well established that the GABAB1 and GABAB2 subunits of
GABABRs are allosterically coupled through multiple interactions in
their extracellular and transmembrane domains (Monnier et al.,
2011). Likewise, GABABRs undergo allosteric interactions with the
G-protein (Hill et al., 1984; Pin et al., 2004). Constitutive association
of GABABRs with auxiliary KCTD subunits not only generates
molecularly distinct receptor subtypes but also introduces the
KCTDs as novel factors that potentially allosterically regulate the
ternary receptor complex (Gassmann and Bettler, 2012; Schwenk
et al., 2010). The KCTDs bind to both receptor and G-protein,
which inﬂuences the kinetics of the receptor response through
stabilizing the G-protein at the receptor and through direct effects
on G-protein signaling (Turecek et al., 2014). In principle, the KCTDs
could allosterically regulate the receptor through direct effects at
GABAB2 and/or through indirect effects at the receptor-associated
Fig. 5. Effects of the KCTDs on allosteric modulation of GABABR-activated Kir3 currents in transfected CHO cells. (A) Representative traces of GABAB-activated Kir3 currents recorded
at 50 mV from CHO-GABAB cells co-expressing Kir3 channels with or without KCTD proteins. Control traces evoked by 1 mM baclofen (Bac) are shown in gray (- GS), traces evoked
by co-application of 1 mM baclofen þ 10 mM of GS39783 in black (þGS). Pre-incubation with GS39783 by bath was for 10 min. Scaling: 10 pA/10 s. (B) Summary bar graphs showing
the effect of GS39783 on peak amplitude, relative desensitization and rise-time of Kir3 currents. ø KCTD, white; þKCTD8, black; þKCTD12, light gray; þKCTD16, dark gray. Data are
expressed as mean ± S.E.M.; *, p < 0.05, ManneWhitney test on paired data.
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like the KCTDs, bind to GABAB2. PAMs at GABABRs increase both
agonist binding-afﬁnity and efﬁcacy of the receptor response (May
et al., 2007; Urwyler et al., 2003), showing that PAMs modulate
both the orthosteric agonist binding-site and G-protein activation.
PAMs may therefore also inﬂuence interactions between the KCTDs
and the G-protein. In our studies we have addressed whether the
KCTDs allosterically inﬂuence (i) the orthosteric agonist binding-
site, (ii) G-protein activation and (iii) modulation by GS39783.
Our data indicate that the KCTDs exert per se little allosteric inﬂu-
ence on the orthosteric agonist binding-site or on G-protein acti-
vation. This shows that the increase in GABA potency observed in
the presence of KCTDs with receptor-activated Kir3 currentsFig. 6. Effects of the KCTDs on allosteric modulation of GABABR-activated Kþ currents in
native neurons. Representative traces of GABAB-activated Kir3 currents recorded
at50 mV from cultured hippocampal neurons of wild-type (WT, left) or Kctd8/12/16/
triple knockout mice (3KO, right). 1 mM of baclofen (Bac, black bars) was applied for 90 s,
then 10 mM of GS39783 (þGS, gray bars) was co-applied for an additional 90 s. Scaling:
10 pA/1 min.(Schwenk et al., 2010) is not due to an increase in agonist binding-
afﬁnity but relates to KCTD effects on the G-protein cycle. The ef-
fects on the G-protein cycle are lost in the [35S]GTPgS binding ex-
periments, in which the G-protein cycle is interrupted. Allosteric
regulation of the receptor complex by GS39783 is qualitatively
similar in the absence and presence of the KCTDs. This further
supports that the KCTDs primarily regulate the receptor response at
the G-protein (Turecek et al., 2014). Differential regulation of the
G-protein by the KCTDs, however, causes signiﬁcant quantitative
differences in the modulatory effect of GS39783 on the efﬁcacy of
the receptor response (KCTD8) or the increase in the relative
desensitization of receptor-activated Kþ-currents (KCTD12) in
transfected cells. However, we did not observe signiﬁcant differ-
ences between the modulatory effect of GS39783 on native re-
ceptors inWTand 3KOmice. This is likely due to the fact that native
GABABRs are heterogeneous. Whereas the GABAB1 and GABAB2
protomers are expressed by almost all neurons and glial cells
(Gassmann and Bettler, 2012), the repertoire and abundance of the
KCTDs varies among brain areas, neuronal populations and sub-
cellular sites (Metz et al., 2011; Schwenk et al., 2010). Moreover, a
signiﬁcant fraction of native GABABRs in the brain is devoid of any
KCTDs (Turecek et al., 2014). Thus, it is likely that native GABABRs
assembled with speciﬁc KCTDs are also differentially modulated by
GS39783, similar to the GABABRs reconstituted with KCTDs in
transfected cells, but that the responses of individual receptor
populations are masked in the overall response of different re-
ceptor populations.
The agonist binding experiments show that the KCTDs fail to
increase agonist binding-afﬁnity at recombinant GABABRs to the
level of native receptors. This suggests that other factors are
responsible for the higher agonist binding-afﬁnity of native
GABABRs. Candidate factors are additional binding partners of
GABABRs (Schwenk et al., 2010) or posttranslational modiﬁcations
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the GABAB1 and GABAB2 subunits (Couve et al., 2002; Guetg et al.,
2010; Kuramoto et al., 2007).
KCTD8 reduces basal G-protein activation in the [35S]GTPgS
binding assay. Reduced basal G-protein activation can to some
extent be overcome with GS39783, which induces a larger increase
in efﬁcacy with KCTD8 than with the other KCTDs. A similar phe-
nomenon has been observed with partial agonists that are more
amenable to allosteric modulation by PAMs than full agonists. This
was for example shown with GABABRs (Mannoury la Cour et al.,
2008; Urwyler et al., 2005) and mGlu2 receptors (Schaffhauser
et al., 2003). This supports that a less efﬁcacious G-protein
coupling e either due to the effects of a partial agonist or the
presence of KCTD8 e allows for a bigger total increase in efﬁcacy in
the presence of the PAM. Consistent with a unique effect of KCTD8
on basal G-protein activation we selectively observed a change in
the basal BRET between G-protein subunits in the combined
presence of KCTD8 and GABABRs. KCTD8, when associated with
GABABRs, therefore likely induces a conformational change in the
G-protein that reduces basal G-protein activation by the receptor.
Of note, the BRETexperiments allow for the ﬁrst time to distinguish
KCTD8 and KCTD16 in a functional assay system.
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